Company: CDT
Filing Date: 2025-04-02
Form Type: 8-K/A
Source: 0001641172-25-002400
Chunk: 1

Company: CDT Equity Inc.
Filing Date: 2025-04-02
Form: 8-K/A
Chunk 1
---
                                                             
 Warrants, each whole warrant exercisable for one share of Common Stock |     | CDTTW     |     | The                                  
 Nasdaq Stock Market LLC              |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K previously filed by Conduit Pharmaceuticals Inc. (the “Company”) with the Securities and Exchange Commission on April 1, 2025 (the “Original Report”). The Company is filing this Amendment in order to include specific information required by Nasdaq. This Amendment amends and restates the Original Report.

Item 8.01. Other Events

Nasdaq Deficiency Compliance Update

On March 7, 2025, the Company applied to the Nasdaq Capital Market and is currently compliant with the Market Value of Publicly Held Securities continued listing standard of Nasdaq Capital Market being greater than $1.0 million. On March 31, 2025, the Company submitted to Nasdaq on a pro-forma basis, as of March 31, 2025, a financial statement demonstrating its compliance with the Nasdaq Capital Market Equity Standard of Stockholder’s Equity greater than $2.5 million, after anticipating all first quarter 2025 expected losses, reflecting Stockholder’s Equity of $2.8 million, which has significantly increased since the Company’s fiscal year end as a result of (i) fundraising of an additional $8.332 million from the Company’s ongoing at the market offering, (ii) conversion of $1.785 million into 924,200 shares of common stock from previously existing debt, and (iii) capitalization of certain invoices and fees. The Company was compliant with the Nasdaq Capital Market Equity Standard of Stockholder’s Equity greater than $2.5 million as of March 31, 2025, and continues to remain compliant as of the date of